Research progress on action mechanism and preparation of monoclonal antibodies against 2019-nCoV.
Chinese Journal of Clinical Infectious Diseases
; 14(2):91-96, 2021.
Artículo
en Chino
| EMBASE | ID: covidwho-2287852
ABSTRACT
During the treatment of critically ill COVID-19 patients it has been revealed that the neutralizing monoclonal antibodies against 2019-nCoV have the advantages of high specificity, high purity, and can be prepared in a large scale, which are expected to be a effective preparation for clinical use. This article introduces the way of 2019-nCoV invasion into the host cells, the major variants of novel coronavirus, and the mechanism of action of anti-2019-nCoV monoclonal antibodies, as well as the progress of research and development of their preparation in major pharmaceutical companies, to provide reference for scientific research and clinical application.Copyright © Chinese Journal of Clinical Infectious Diseases.All rights reserved.
2019-nCoV, Antibodie; monoclonal, Antibodie; neutralizing, js016, Meplazumab, REGN-CoV2 cocktail therapy, Transmembrane protease, Variant, article, coronavirus disease 2019, drug mechanism, drug research, host cell, monoclonal antibody therapy, nonhuman, priority journal, Severe acute respiratory syndrome coronavirus 2, virus strain, monoclonal antibody
Texto completo:
Disponible
Colección:
Bases de datos de organismos internacionales
Base de datos:
EMBASE
Idioma:
Chino
Revista:
Chinese Journal of Clinical Infectious Diseases
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS